poorly differentiated thyroid gland carcinomapoorly differentiated thymic neuroendocrine carcinoma+1 moreResearch
A recent study published in PubMed evaluates the clinical outcomes of pembrolizumab combination therapy in patients with heavily pretreated poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid cancer. The findings contribute to understanding treatment efficacy in these challenging cancer types.
clinical outcomes of pembrolizumab combination therapy in heavily pretreated pdtc and anaplastic thyroid cancer
Original title: “Clinical Outcomes of Pembrolizumab Combination Therapy in Heavily Pretreated PDTC and Anaplastic Thyroid Cancer.”